BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hoi AY, Morand EF. Treatment Update in Systemic Lupus Erythematous. Rheum Dis Clin North Am 2021;47:513-30. [PMID: 34215377 DOI: 10.1016/j.rdc.2021.04.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Zeng H, Chen S, Lu X, Yan Z. Investigating the molecular mechanism of iguratimod act on SLE using network pharmacology and molecular docking analysis. Front Bioinform 2022;2. [DOI: 10.3389/fbinf.2022.932114] [Reference Citation Analysis]
2 Nataraja C, Flynn J, Dankers W, Northcott M, Zhu W, Sherlock R, Bennett TJ, Russ BE, Miceli I, Pervin M, D'Cruz A, Harris J, Morand EF, Jones SA. GILZ regulates type I interferon release and sequesters STAT1. J Autoimmun 2022;131:102858. [PMID: 35810690 DOI: 10.1016/j.jaut.2022.102858] [Reference Citation Analysis]
3 Lamb YN. Anifrolumab in systemic lupus erythematosus: a profile of its use. Drugs Ther Perspect 2022;38:293-300. [DOI: 10.1007/s40267-022-00925-7] [Reference Citation Analysis]
4 Qing J, Song W, Tian L, Samuel SB, Li Y, Wan C. Potential Small Molecules for Therapy of Lupus Nephritis Based on Genetic Effect and Immune Infiltration. BioMed Research International 2022;2022:1-16. [DOI: 10.1155/2022/2259164] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
5 Cronstein BN. SLE and purine metabolizing ecto-enzymes. EBioMedicine 2021;74:103688. [PMID: 34773894 DOI: 10.1016/j.ebiom.2021.103688] [Reference Citation Analysis]